Tudor Investment Corp ET AL Acquires 23,893 Shares of Neurocrine Biosciences, Inc. $NBIX

Tudor Investment Corp ET AL raised its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 805.3% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 26,860 shares of the company’s stock after buying an additional 23,893 shares during the quarter. Tudor Investment Corp ET AL’s holdings in Neurocrine Biosciences were worth $3,771,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Allworth Financial LP grew its position in shares of Neurocrine Biosciences by 68.1% during the 3rd quarter. Allworth Financial LP now owns 5,009 shares of the company’s stock worth $703,000 after buying an additional 2,029 shares during the period. IFP Advisors Inc boosted its stake in Neurocrine Biosciences by 14.0% during the third quarter. IFP Advisors Inc now owns 2,475 shares of the company’s stock worth $347,000 after acquiring an additional 303 shares in the last quarter. Swiss Life Asset Management Ltd grew its holdings in Neurocrine Biosciences by 31.9% in the third quarter. Swiss Life Asset Management Ltd now owns 17,767 shares of the company’s stock worth $2,494,000 after purchasing an additional 4,293 shares during the period. CIBC Private Wealth Group LLC grew its holdings in Neurocrine Biosciences by 17,250.0% in the third quarter. CIBC Private Wealth Group LLC now owns 7,981 shares of the company’s stock worth $1,120,000 after purchasing an additional 7,935 shares during the period. Finally, CIBC Bancorp USA Inc. bought a new stake in Neurocrine Biosciences in the third quarter valued at $498,000. 92.59% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, CEO Kyle Gano sold 36,400 shares of the stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $132.70, for a total value of $4,830,280.00. Following the completion of the sale, the chief executive officer directly owned 140,407 shares of the company’s stock, valued at $18,632,008.90. This represents a 20.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 4.80% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on NBIX. HC Wainwright cut their price objective on shares of Neurocrine Biosciences from $198.00 to $192.00 and set a “buy” rating on the stock in a research report on Thursday, February 12th. Wolfe Research assumed coverage on Neurocrine Biosciences in a research report on Tuesday, February 24th. They issued an “outperform” rating and a $160.00 target price for the company. JPMorgan Chase & Co. upped their price target on Neurocrine Biosciences from $176.00 to $177.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Zacks Research lowered Neurocrine Biosciences from a “hold” rating to a “strong sell” rating in a report on Tuesday, February 17th. Finally, BMO Capital Markets reduced their price objective on Neurocrine Biosciences from $147.00 to $140.00 and set a “market perform” rating for the company in a research note on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $175.10.

Neurocrine Biosciences Price Performance

Shares of NASDAQ NBIX opened at $132.42 on Friday. The company has a 50-day moving average price of $132.04 and a 200-day moving average price of $139.63. The stock has a market capitalization of $13.29 billion, a P/E ratio of 28.42, a P/E/G ratio of 0.68 and a beta of 0.32. Neurocrine Biosciences, Inc. has a 1 year low of $84.23 and a 1 year high of $160.18.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Wednesday, February 11th. The company reported $1.88 earnings per share for the quarter, missing analysts’ consensus estimates of $2.36 by ($0.48). Neurocrine Biosciences had a return on equity of 16.48% and a net margin of 16.73%.The business had revenue of $805.50 million during the quarter, compared to analyst estimates of $804.21 million. During the same quarter in the prior year, the company earned $1.69 EPS. The company’s revenue was up 28.3% on a year-over-year basis. As a group, equities research analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Neurocrine Biosciences Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.